AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
197.69
+0.31 (0.16%)
At close: Apr 28, 2026, 4:00 PM EDT
197.99
+0.30 (0.15%)
After-hours: Apr 28, 2026, 7:59 PM EDT
AbbVie Employees
AbbVie had 57,000 employees as of December 31, 2025. The number of employees increased by 2,000 or 3.64% compared to the previous year.
Employees
57,000
Change (1Y)
2,000
Growth (1Y)
3.64%
Revenue / Employee
$1,072,982
Profits / Employee
$73,439
Market Cap
349.67B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 57,000 | 2,000 | 3.64% |
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| Eli Lilly and Company | 50,000 |
ABBV News
- 16 hours ago - AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata - PRNewsWire
- 17 hours ago - EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie - GlobeNewsWire
- 1 day ago - AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease - PRNewsWire
- 5 days ago - US FDA declines to approve AbbVie's wrinkle treatment - Reuters
- 5 days ago - AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S. - PRNewsWire
- 6 days ago - AbbVie to build $1.4 billion manufacturing campus in North Carolina - Reuters
- 6 days ago - AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus - PRNewsWire
- 8 days ago - Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases - GlobeNewsWire